Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study
Zhong-Tai Lin,Shao-Ming Wei,Jun-Yi Wu,Zhi-Bo Zhang,Shuang-Jia Wang,Jian-Yin Zhou,Meng-Chao Luo,Zhen-Xin Zeng,Xiang-Ye Ou,Yang-Kai Fu,Han Li,De-Yi Liu,Jia-Yi Wu,Mao-Lin Yan
DOI: https://doi.org/10.2147/jhc.s477019
2024-09-25
Journal of Hepatocellular Carcinoma
Abstract:Zhong-Tai Lin, 1, 2, &ast Shao-Ming Wei, 1, 3, &ast Jun-Yi Wu, 1, 3, &ast Zhi-Bo Zhang, 4 Shuang-Jia Wang, 5 Jian-Yin Zhou, 6 Meng-Chao Luo, 1, 3 Zhen-Xin Zeng, 1 Xiang-Ye Ou, 1 Yang-Kai Fu, 1 Han Li, 1 De-Yi Liu, 1 Jia-Yi Wu, 1, 3 Mao-Lin Yan 1, 3 1 The Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, People's Republic of China; 2 Department of Gastrointestinal Surgery, Fujian Provincial Hospital, Fuzhou, Fujian Province, People's Republic of China; 3 Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian Province, People's Republic of China; 4 Department of Hepatopancreatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, People's Republic of China; 5 Department of Hepato-Biliary-Pancreatic and Vascular Surgery, First Affiliated Hospital of Xiamen University, Xiamen, Fujian Province, People's Republic of China; 6 Department of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Xiamen, Fujian Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jia-Yi Wu; Mao-Lin Yan, The Shengli Clinical Medical College of Fujian Medical University, Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Dongjie Road 134, Fuzhou, Fujian Province, 350001, People's Republic of China, Tel +86 0591-88217140, Fax +86 0591-87557768, Email ; Background: This study aimed to assess the effect of adjuvant therapy with different durations in patients with initially unresectable hepatocellular carcinoma (uHCC) after conversion surgery. Methods: This study included 85 patients with initially uHCC who received conversion surgery between May 2019 and November 2022. They were divided into the long duration group (n = 57) and short duration group (n = 28) based on postoperative medication duration. Recurrence-free survival (RFS) and overall survival (OS) were analyzed and compared between the cohorts. Results: No significant difference in RFS or OS was found between the two groups [RFS: hazard ratio (HR) = 0.486; 95% confidence interval (CI), 0.229– 1.034, P = 0.061; OS: HR = 0.377; 95% CI, 0.119– 1.196, P = 0.098]. Patients without major pathologic response (MPR) in the long duration group had better RFS and OS results compared to those in the short duration group (RFS: HR = 0.242; 95% CI, 0.092– 0.634, P = 0.004; OS: HR = 0.264; 95% CI, 0.079– 0.882, P = 0.031). No significant difference was detected in RFS or OS between the two groups in patients with MPR (RFS: HR = 1.250; 95% CI, 0.373– 4.183, P = 0.718; OS: HR = 7.389; 95% CI, 0.147– 372.4, P = 0.317). After propensity score matching, 25 pairs of patients were selected and the results remained consistent. Conclusion: At least 6 months of adjuvant therapy may be beneficial for patients without MPR after conversion surgery. However, in patients with MPR, the effect of adjuvant therapy remains unclear. Further studies are needed to confirm the optimal duration of adjuvant therapy. Keywords: unresectable, hepatocellular carcinoma, conversion therapy, adjuvant therapy, recurrence-free survival, overall survival Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and a primary factor in global cancer-related mortality. 1 To date, surgical resection remains the most effective treatment for HCC. 2,3 However, given the insidious nature of HCC, most patients are diagnosed at an intermediate or advanced stage and are ineligible for curative resection. 4 For patients with unresectable HCC (uHCC), conversion therapy is the mainstay of treatment. 5,6 Conversion therapy is a strategy that aims to convert unresectable tumors into resectable ones followed by surgery to remove the tumors. Sorafenib was approved for the therapy of advanced HCC in 2007. However, it has a low objective response rate (ORR) and conversion rate. 7–9 With the development of targeted drugs and immune checkpoint inhibitors, the conversion rate for uHCC has experienced a significant increase, and the overall survival (OS) and progression-free survival (PFS) of patients have improved. 10–12 IMbrave150 showed that the median OS, median PFS, and ORR were significantly better in the atezolizumab and bevacizumab groups than those in the sorafenib group (median OS: 19.2 months vs 13.4 months, p < 0.001; median PFS: 6.9 months vs 4.3 months, p < 0.001 -Abstract Truncated-
oncology